StockData
Champions Oncology, Inc. logo

Champions Oncology, Inc. (CSBR) stock

CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30238% above fair value
$4.59−0.09 (-1.89%)

Close on Nov 17, 2026Market cap $63.91MP/E –Yield –

Champions Oncology pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Champions Oncology's pe ratio was 35.0× on Feb 27, 2026, against 465.0× a year earlier. Over the last 3 years it ranged from 13.3× to 977.0×, with a median of 250.0×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Feb 27, 202635.0×−5.6
2025Dec 31, 202540.6×−424.4
2023Feb 28, 2023465.0×+14.0
2022Dec 30, 2022451.0×+172.3
2021Dec 31, 2021278.7×−261.3
2019Aug 30, 2019540.0×–

More Champions Oncology figures

See a number that looks wrong?